文献速递其他结缔组织病

系统性硬化症相关间质性肺病中肺动脉高压的患病率、治疗与结局

Prevalence, Treatment, and Outcomes of Coexistent Pulmonary Hypertension and Interstitial Lung Disease in Systemic Sclerosis.
PubMed 文献 · Arthritis Rheumatol · 2019-06-18

该前瞻性观察队列纳入93例系统性硬化症相关间质性肺病(SSc-ILD)患者,按标准化算法筛查并经右心导管确诊肺动脉高压(PH)。31.2%存在右心导管证实的PH,多数为WHO第3组,常在SSc起病7年内诊断,多数接受ILD及PAH治疗,生存良好。

要点

  • SSc-ILD患者中31.2%经右心导管确诊PH,应常规评估共存PH。
  • 确诊PH者中55.2%为WHO第3组PH,24.1%为PAH。
  • 48.3%的PH在SSc起病7年内诊断,提示PH可早期出现。

核心结论

  • 在SSc-ILD大型队列中,相当比例患者共存PH,且常在SSc诊断后早期出现,多数接受ILD和PAH治疗,生存良好。

研究设计与样本

  • 前瞻性观察队列纳入93例经高分辨率CT诊断的SSc-ILD患者,按标准化算法筛查PH,必要时行右心导管检查,PH分类基于血流动力学和HRCT间质性肺病范围。

主要发现

  • 93例SSc-ILD患者中76%为女性,65.6%为弥漫性皮肤型SSc,平均年龄54.9岁,平均SSc病程8年。
  • 29例(31.2%)有右心导管证实的PH;其中24.1%为PAH,55.2%为WHO第3组PH,34.5%为WHO第3组PH且肺血管阻力>3.0 Wood单位。
  • 48.3%的PH在SSc起病7年内诊断,82.8%接受ILD治疗,82.8%接受PAH治疗。
  • 所有患者SSc-ILD诊断后3年生存率为97%;SSc-ILD合并PH患者PH诊断后3年生存率为91%。

临床怎么用

  • 对SSc-ILD患者应按标准化算法筛查并评估共存PH,必要时行右心导管检查确诊。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Systemic sclerosis (SSc) is associated with interstitial lung disease (ILD) and pulmonary hypertension (PH). This study was undertaken to determine the prevalence, characteristics, treatment, and outcomes of PH in a cohort of patients with SSc-associated ILD. METHODS: Patients with SSc-associated ILD on high-resolution computed tomography (HRCT) were included in a prospective observational cohort. Patients were screened for PH based on a standardized screening algorithm and underwent right-sided heart catheterization (RHC) if indicated. PH classification was based on hemodynamic findings and the extent of ILD on HRCT. Summary statistics and survival using the Kaplan-Meier method were calculated. RESULTS: Of the 93 patients with SSc-associated ILD included in the study, 76% were women and 65.6% had diffuse cutaneous SSc. The mean age was 54.9 years, and the mean SSc disease duration was 8 years. Twenty-nine patients (31.2%) had RHC-proven PH; of those 29 patients, 24.1% had PAH, 55.2% had World Health Organization (WHO) Group III PH, 34.5% had WHO Group III PH with pulmonary vascular resistance >3.0 Wood units, 48.3% had a PH diagnosis within 7 years of SSc onset, 82.8% received therapy for ILD, and 82.8% received therapy for PAH. The survival rate 3 years after SSc-associated ILD diagnosis for all patients was 97%. The survival rate 3 years after PH diagnosis for those with SSc-associated ILD and PH was 91%. CONCLUSION: In a large cohort of patients with SSc-associated ILD, a significant proportion of patients had coexisting PH, which often occurs early after SSc diagnosis. Most patients were treated with ILD and PAH therapies, and survival was good. Patients with SSc-associated ILD should be evaluated for coexisting PH.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Young A, Vummidi D, Visovatti S, et al. Prevalence, Treatment, and Outcomes of Coexistent Pulmonary Hypertension and Interstitial Lung Disease in Systemic Sclerosis. Arthritis Rheumatol. 2019. PMID: 30762947. doi:10.1002/art.40862

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。